- 博士生导师
- 硕士生导师
- 电子邮箱：
- 入职时间：2013-12-25
- 性别：女
- 在职信息：在职
- 所属院系：第一附属医院
- 学科：临床医学
- Zhang Y, Liang L, Li H, Cao Y, Meng D, Li X, Wang M, Wang J, Yao Y, Zhang S, Chen C*, Hou P*, Yang Q*. Smart multi-functional aggregates reoxygenate tumor microenvironment through a two-pronged strategy to revitalize cancer immunotherapy. Aggregate. 2024. Online published. (IF: 18.8)
- Yang Q, Jiang W, Hou P*. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112-124. (IF: 14.5)
- Yang Q and Hou P*. Targeting PFKFB3 in the Endothelium for Cancer Therapy. Trends Mol Med. 2017;23(3):197-200. (IF: 13.6)
- Ruan B, Liu W, Chen P, Cui R, Li Y, Ji M, Hou P*, Yang Q*. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation. International journal of biological sciences 2020; 16: 682-693. (IF:9.2)
- Dang S, Zhou J, Chen Y, Chen P, Ji M, Shi B, Yang Q*, Hou P*. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019; 38(24):4804-4819. (IF:8.0)
- Yang Q*, Dang H, Liu J, Wang X, Wang J, Lan X, Ji M*, Xing M*, Hou P*. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023; 42(20):1634-8. (IF:8.0)
- Wang N, Sui F, Ma J, Su X, Liu J, Yao D, Shi B, Hou P*, Yang Q*. Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer. Archives of medical research 2016; 47: 285-292. (IF:7.7)
- Zhang Y, Zhang Z, Ma J, Pu J, Hou P*, Yang Q*. High-accuracy Detection of Preoperative Thyroid Nodules Using Combination of BRAF(V600E) Mutation and TMPRSS4 mRNA Level. Archives of medical research 2018; 49: 365-372. (IF:7.7)
- Cui B#, Yang Q#, Guan H, Shi B, Hou P*, Ji M*. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 5.8)
- Yang Q, Ji M, Guan H, Shi B, Hou P*. Shikonin Inhibits Thyroid Cancer Cell Growth and Invasiveness through Targeting Major Signaling Pathways. J Clin Endocrinol Metab. 2013; 98(12):E1909-17. (IF: 5.8)
- Qui Y#, Yang Q#, Sui F, Lu R, Dang S, Ji M, HE N, Shi B, Hou P*. A Strategy for Accurate Quantification of 5-Methylcytosine and 5-Hydroxymethylcytosine at CpG Sites Within Gene Promoter. J Biomed Nanotechnol 2015; 11: 1016-1026. (IF:2.9)
- Yang Q, Wu K, Ji M, Jin W, He N, Shi B, Hou P*. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol 2013; 9: 1607-1616. (IF:2.9)
- Yang Q, Shao Y, Shi J, Qu Y, Wu K, Dang S, Shi B, Hou P*. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clinical biochemistry 2014; 47: 111-116. (IF:2.8)
- Li X, Pu J, Liu J, Chen Y, Li Y, Hou P, Shi B, Yang Q*. The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis. Pathology, research and practice 2018; 214: 940-948. (IF:2.8)
- Lv Y, Zhang Y, Li X, Ren X, Wang M, Tian S, Hou P, Shi B, Yang Q*. Long telomere length predicts poor clinical outcome in esophageal cancer patients. Pathology, research and practice 2017; 213: 113-118. (IF:2.8)
- 杨琪(2/9); 消化道肿瘤关键预后分子的基础研究, 陕西省人民政府, 科技进步, 省部二等奖, 2019(侯鹏; 杨琪; 曲以平; 姚德茂; 邵渊; 陈谱; 李梦丹; 石静; 申震)